174 related articles for article (PubMed ID: 23223537)
1. Higher macular volume in patients with MS receiving fingolimod: positive outcome or side effect?
Dinkin M; Paul F
Neurology; 2013 Jan; 80(2):128-9. PubMed ID: 23223537
[TBL] [Abstract][Full Text] [Related]
2. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing-remitting multiple sclerosis.
Winges KM; Werner JS; Harvey DJ; Cello KE; Durbin MK; Balcer LJ; Calabresi PA; Keltner JL
J Neuroophthalmol; 2013 Dec; 33(4):322-9. PubMed ID: 24051419
[TBL] [Abstract][Full Text] [Related]
3. Fingolimod treatment in multiple sclerosis leads to increased macular volume.
Nolan R; Gelfand JM; Green AJ
Neurology; 2013 Jan; 80(2):139-44. PubMed ID: 23223539
[TBL] [Abstract][Full Text] [Related]
4. Fingolimod therapy and macular hemorrhage.
Bhatti MT; Freedman SM; Mahmoud TH
J Neuroophthalmol; 2013 Dec; 33(4):370-2. PubMed ID: 23845997
[TBL] [Abstract][Full Text] [Related]
5. Fingolimod for multiple sclerosis: a review for the specialist nurse.
Harrison K
Br J Nurs; 2014 Jun 12-25; 23(11):582-9. PubMed ID: 24933548
[TBL] [Abstract][Full Text] [Related]
6. [Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature].
Shmyrev VI; Kryzhanovskiĭ SM; Danilycheva IV
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):93-7. PubMed ID: 22677684
[TBL] [Abstract][Full Text] [Related]
7. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.
Ward MD; Jones DE; Goldman MD
Expert Opin Drug Saf; 2014 Jul; 13(7):989-98. PubMed ID: 24935480
[TBL] [Abstract][Full Text] [Related]
8. [Fingolimod treatment in multiple sclerosis].
Tanaka M
Nihon Rinsho; 2014 Nov; 72(11):2010-4. PubMed ID: 25518386
[TBL] [Abstract][Full Text] [Related]
9. Fingolimod therapy for multiple sclerosis.
Willis MA; Cohen JA
Semin Neurol; 2013 Feb; 33(1):37-44. PubMed ID: 23709211
[TBL] [Abstract][Full Text] [Related]
10. Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions.
Mehling M; Kappos L; Derfuss T
Curr Neurol Neurosci Rep; 2011 Oct; 11(5):492-7. PubMed ID: 21789537
[TBL] [Abstract][Full Text] [Related]
11. Ventricular tachycardia on chronic fingolimod treatment for multiple sclerosis.
Castillo-Trivino T; Lopetegui I; Alarcón-Duque JA; López de Munain A; Olascoaga J
J Neurol Neurosurg Psychiatry; 2015 Aug; 86(8):931-2. PubMed ID: 25835036
[No Abstract] [Full Text] [Related]
12. New drugs may improve, complicate treatment for multiple sclerosis.
Link H; Martin R
Nat Med; 2010 Mar; 16(3):272. PubMed ID: 20208513
[No Abstract] [Full Text] [Related]
13. Multiple sclerosis, immunomodulation, and immunizations: balancing the benefits.
Goldman MD; Naismith RT
Neurology; 2015 Mar; 84(9):864-5. PubMed ID: 25636716
[No Abstract] [Full Text] [Related]
14. Famous.
Kim MJ; Bhatti MT; Costello F
Surv Ophthalmol; 2016; 61(4):512-9. PubMed ID: 26742785
[TBL] [Abstract][Full Text] [Related]
15. [A plan for risk management in the treatment of multiple sclerosis with gilenia (fingolimod)].
Popova NF
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):110-3. PubMed ID: 21916166
[No Abstract] [Full Text] [Related]
16. Longitudinal quantitative assessment of macula during therapy with fingolimod in relapsing-remitting multiple sclerosis.
Fruschelli M; Capozzoli M; Gelmi MC; Masi G; Annunziata P
Int Ophthalmol; 2019 Apr; 39(4):777-781. PubMed ID: 29500696
[TBL] [Abstract][Full Text] [Related]
17. Fingolimod: a novel immunosuppressant for multiple sclerosis.
Brown BA; Kantesaria PP; McDevitt LM
Ann Pharmacother; 2007 Oct; 41(10):1660-8. PubMed ID: 17785617
[TBL] [Abstract][Full Text] [Related]
18. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of fingolimod on B-cell populations in multiple sclerosis.
Nakamura M; Matsuoka T; Chihara N; Miyake S; Sato W; Araki M; Okamoto T; Lin Y; Ogawa M; Murata M; Aranami T; Yamamura T
Mult Scler; 2014 Sep; 20(10):1371-80. PubMed ID: 24526661
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of fingolimod.
David OJ; Kovarik JM; Schmouder RL
Clin Pharmacokinet; 2012 Jan; 51(1):15-28. PubMed ID: 22149256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
